Treatment Approach for Prostate Cancer Gleason 7

Risk Classification and Assessment

The European Association of Urology classifies Gleason 7 prostate cancer as intermediate-risk disease, with further risk stratification depending on PSA level, primary Gleason pattern, percentage of positive biopsy cores, and clinical stage 1, 3
A PSA level of 10-20 ng/mL increases the risk of prostate cancer progression 1
The percentage of positive biopsy cores is a significant factor in determining the risk of prostate cancer progression 4
Clinical stage T2a or higher increases the risk of prostate cancer progression 3

The American Urological Association recommends radical prostatectomy as a standard treatment option for patients with intermediate-risk disease and life expectancy >10 years 2, 5
Radical prostatectomy benefits include complete removal of the prostate with accurate pathological staging, but potential complications include erectile dysfunction (up to 80% of patients) and urinary incontinence (up to 49% of patients) 2, 3
External beam radiation therapy (EBRT) is an effective treatment option for intermediate-risk disease, with a recommended minimum target dose of 70 Gy given in 2.0 Gy fractions, and consideration of adding androgen deprivation therapy (ADT) for 4-6 months 2, 3
Brachytherapy can be used as monotherapy or as a boost with EBRT, with low-dose rate (LDR) brachytherapy alone recommended for patients with low-intermediate risk prostate cancer (Gleason 7, PSA <10 ng/mL) 6, 1
Active surveillance may be considered for selected patients with Gleason 3+4=7 disease, particularly those with comorbidities or limited life expectancy, with a protocol including PSA monitoring every 6 months and repeat prostate biopsy within 12 months 1

The National Comprehensive Cancer Network recommends assessing patient factors, including age and life expectancy, comorbidities and surgical risk, and urinary function, to determine the most appropriate treatment option 2, 5, 1
Disease characteristics, including primary Gleason pattern, PSA level and density, clinical stage, and percentage of positive cores, should also be assessed to determine the most appropriate treatment option 2, 1, 3, 4

The European Association of Urology does not recommend primary ADT alone as standard initial treatment for localized prostate cancer 2, 1
Adjuvant radiotherapy immediately following radical prostatectomy has not been shown to improve survival, according to the American Society of Clinical Oncology 3
Brachytherapy can exacerbate urinary obstructive symptoms and should be used cautiously in patients with significant lower urinary tract symptoms, as recommended by the American Urological Association 1
Patients should be informed that ADT with radiation increases adverse effects on sexual function, according to the National Comprehensive Cancer Network 1
Older men experience higher rates of permanent erectile dysfunction and urinary incontinence after prostatectomy compared to younger men, as reported by the American Urological Association 1